Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 24, 2023
- Revision received November 7, 2023
- Published online February 1, 2024.
Article Versions
- previous version (January 4, 2024 - 06:54).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Rainer Hamacher1,2,
- Kim M. Pabst2,3,
- Phyllis F. Cheung4,5,
- Christoph E. Heilig6,7,
- Jennifer Hüllein8,
- Sven-Thorsten Liffers4,5,
- Sabrina Borchert2,9,
- Pedro Fragoso Costa2,3,
- Benedikt M. Schaarschmidt2,10,
- Lukas Kessler2,3,
- Monika A. Miera1,4,
- Margret Droste4,5,
- Merve Akbulut1,
- Johanna Falkenhorst1,2,
- Fadi Zarrad2,3,
- Karina Kostbade1,2,
- Ilektra A. Mavroeidi1,2,
- Hanno Glimm11,12,13,14,15,16,
- Lale Umutlu2,10,
- Martin Schuler1,2,
- Daniel Hübschmann7,8,17,
- Sebastian Bauer1,2,
- Stefan Fröhling6,7,
- Ken Herrmann2,3,
- Jens T. Siveke1,2,4,5,
- Hans-Ulrich Schildhaus*,2,9 and
- Wolfgang P. Fendler*,2,3
- 1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 2German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany;
- 3Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 4Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 5Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany;
- 6Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany;
- 7German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany;
- 8Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany;
- 9Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 10Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 11Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany;
- 12German Cancer Research Center, Heidelberg, Germany;
- 13Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;
- 14Helmholtz-Zentrum Dresden–Rossendorf, Dresden, Germany;
- 15Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;
- 16German Cancer Consortium, Dresden, Germany; and
- 17Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany
- For correspondence or reprints, contact Rainer Hamacher (rainer.hamacher{at}uk-essen.de).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy
- Are FAP Theranostics Really Happening? Will Radiochemistry or Biology Win?
- Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors
- 1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?